Baser, M.N.; Demir, B.; Serin Ozel, G.; Dogu, G.G.; Karakaya, S.; Ugar, M.; Ak, N.; Ozveren, A.; Camanlı, U.; Unal, O.U.;
et al. Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study. Medicina 2025, 61, 1230.
https://doi.org/10.3390/medicina61071230
AMA Style
Baser MN, Demir B, Serin Ozel G, Dogu GG, Karakaya S, Ugar M, Ak N, Ozveren A, Camanlı U, Unal OU,
et al. Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study. Medicina. 2025; 61(7):1230.
https://doi.org/10.3390/medicina61071230
Chicago/Turabian Style
Baser, Mehmet Nuri, Bilgin Demir, Gamze Serin Ozel, Gamze Gokoz Dogu, Serdar Karakaya, Mucahit Ugar, Naziye Ak, Ahmet Ozveren, Ufuk Camanlı, Olcun Umit Unal,
and et al. 2025. "Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study" Medicina 61, no. 7: 1230.
https://doi.org/10.3390/medicina61071230
APA Style
Baser, M. N., Demir, B., Serin Ozel, G., Dogu, G. G., Karakaya, S., Ugar, M., Ak, N., Ozveren, A., Camanlı, U., Unal, O. U., Turan, M., & Oktay, E.
(2025). Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study. Medicina, 61(7), 1230.
https://doi.org/10.3390/medicina61071230
